US2019175505A1PendingUtilityA1

Combinational liposome compositions for cancer therapy

60
Assignee: MALLINCKRODT LLCPriority: Oct 31, 2011Filed: Feb 19, 2019Published: Jun 13, 2019
Est. expiryOct 31, 2031(~5.3 yrs left)· nominal 20-yr term from priority
Inventors:Jun YangStephen H. WuCliff J. Herman
A61P 35/00A61P 35/02A61K 31/704A61K 31/513A61P 21/00A61K 31/7068A61K 31/337A61K 31/282A61K 31/555A61K 9/1273A61K 9/127A61K 9/0019A61P 25/00A61K 9/1272A61P 19/00A61K 33/24A61K 33/243
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising:
 a therapeutic liposome comprising at least one lipid, at least one therapeutic agent, at least one diagnostic agent, and combinations thereof, wherein the therapeutic agent is an anticancer agent or a cytotoxic agent; and   an attacking liposome comprising at least one lipid and at least one non-ionic triggering agent, and   
       wherein the attacking liposome is sequentially or concurrently administered with the therapeutic liposome to deliver the therapeutic agent to a subject in need thereof, and 
       wherein the pharmaceutical composition is administered to the subject in a dose sufficient to affect a therapeutic response in the subject. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the therapeutic liposome comprises at least one lipid selected from the group consisting of: a phospholipid, a steroid, and a cationic lipid. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the phospholipid is selected from the group consisting of: a phophatidylcholine, a phosphatidylglycerol, a phosphatidylethanolamine, a phosphatidylserine, a phosphatidylinositol, and a phosphatidic acid. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the phosphatidylcholine is distearoyl phosphatidyl choline (DSPC). 
     
     
         5 . The pharmaceutical composition of  claim 3 , wherein the phosphatidylglycerol is distearoyl phosphatidyl glycerol (DSPG). 
     
     
         6 . The pharmaceutical composition of  claim 3 , wherein the phosphatidylethanolamine is DSPE-PEG(2000). 
     
     
         7 . The pharmaceutical composition of  claim 2 , wherein the steroid is cholesterol. 
     
     
         8 . The pharmaceutical composition of  claim 2 , wherein the cationic lipid is N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP). 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the attacking liposome comprises at least one lipid selected from the group consisting of: a second liposome, a micelle, and mixtures thereof. 
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the second liposome comprises one or more lipids selected from the group consisting of a phospholipid, a steroid, and a cationic lipid. 
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein the phospholipid is selected from the group consisting of: a phophatidylcholine, a phosphatidylglycerol, a phosphatidylethanolamine, a phosphatidylserine, a phosphatidylinositol, and a phosphatidic acid. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein the phosphatidylcholine is dipalmitoyl phosphatidyl choline (DPPC). 
     
     
         13 . The pharmaceutical composition of  claim 10 , wherein the steroid is cholesterol. 
     
     
         14 . The pharmaceutical composition of  claim 10 , wherein the cationic lipid is N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP). 
     
     
         15 . The pharmaceutical composition of  claim 1 , wherein the non-ionic triggering agent is D-α-tocopheryl polyethylene glycol succinate (TPGS). 
     
     
         16 . The pharmaceutical composition of  claim 1 , wherein the composition comprises at least one targeting agent. 
     
     
         17 . The pharmaceutical composition of  claim 1 , wherein administration of the attacking liposome increases the release of the therapeutic agent from the therapeutic liposome at least 3-fold, 10-fold, or 25-fold relative to the administration of the therapeutic liposome without use of the attacking liposome. 
     
     
         18 . The pharmaceutical composition of  claim 1 , wherein the therapeutic agent is embedded in the bilayer of the liposome. 
     
     
         19 . The pharmaceutical composition of  claim 1 , wherein the therapeutic agent is encapsulated in the aqueous core of the liposome. 
     
     
         20 . The pharmaceutical composition of  claim 1 , wherein the therapeutic agent is tethered to the exterior of the liposome.

Join the waitlist — get patent alerts

Track US2019175505A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.